Reported Earlier, Arvinas And Pfizer To Present Updated Phase 1/2 Data For Vepdegestrant (ARV-471) At The 2023 European Society For Medical Oncology (ESMO) Annual Congress
Portfolio Pulse from Benzinga Newsdesk
Arvinas and Pfizer will present updated Phase 1/2 data for Vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.
October 16, 2023 | 7:19 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arvinas is set to present updated data on Vepdegestrant, which could influence investor sentiment.
The presentation of updated data on Vepdegestrant by Arvinas at a major medical congress could influence investor sentiment, depending on the results. However, the exact impact is uncertain until the data is revealed.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Pfizer, in partnership with Arvinas, will present updated data on Vepdegestrant, potentially impacting its stock.
Pfizer's presentation of updated data on Vepdegestrant at the ESMO Congress could influence its stock, depending on the results. The exact impact is uncertain until the data is presented.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70